Chakra Biotech Sdn Bhd
Chakra Biotech Sdn Bhd Changes Its Name to Cerca Insights Sdn Bhd
Chakra Biotech Sdn Bhd / 31.05.2010 15:00 Dissemination of a Corporate News, transmitted by DGAP - a company of EquityStory AG. The issuer / publisher is solely responsible for the content of this announcement. --------------------------------------------------------------------------- PENANG, Malaysia, May 31, 2010 (GLOBE NEWSWIRE) -- Chakra Biotech Sdn Bhd today announced its name change to Cerca Insights Sdn Bhd. The name change follows the recent completion of a Series B investment round with Malaysian Life Sciences Capital Fund Ltd (MLSCF) and the Malaysian Technology Development Corporation Sdn Bhd (MTDC). 'The new name reinforces the value of our services,' said Anthony Bishop, CEO of Cerca Insights. 'Cerca, the Italian word for search, reflects our commitment to help pharma and biotech customers discover better medicines for patients, particularly those with psychiatric illness. Insights reflects our vision to provide customers a clear view of the clinical properties in their discovery stage compounds.' Cerca Insights continues to offer customers advanced, novel in-vivo efficacy models to discover, assess, and characterize discovery stage psychiatric and other CNS compounds. Cerca Insights worked with Anderson Baillie Marketing in the UK to create the new name and branding. About Cerca Insights Sdn Bhd Formerly named Chakra Biotech Sdn Bhd, Cerca Insights Sdn Bhd is a Contract Research Organisation (CRO) based in Penang, Malaysia meeting the growing needs of pharma and biotech companies for better ways of assessing their discovery stage psychiatric compounds. The company commenced operations in 2008 and now offers a full range of in-vivo behavioural services. Malaysian Biotechnology Corporation awarded the company Bionexus Status and a Commercialisation Seed Grant. MLSCF and MTDC invested in the Series A and Series B funding rounds. The Cerca Insights Sdn Bhd logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=7272 About MLSCF Ltd The Malaysian Life Sciences Capital Fund (MLSCF) specializes in early stage investments in the areas of agriculture, industrial and healthcare biotechnology. Co-managed by Malaysian Technology Development Corporation Sdn Bhd (MTDC) and Burrill & Company, the fund was founded in late 2006 and currently has USD150 million in committed capital. MLSCF is organized to invest in Leading, Privately Held Life Science companies with Malaysia centricity and deliver on the twin objectives of superior financial results and advancing the life science ecosystem in and for the country of Malaysia. About MTDC Sdn Bhd Malaysia Technology Development Corporation (MTDC) was set up by government of Malaysia in 1992 to spearhead the development of technology businesses in Malaysia. MTDC has evolved to become the leading integrated venture capital solutions provider in Malaysia. To date MTDC have invested more than RM350 million in more than 50 companies. CONTACT: Cerca Insights Sdn Bhd Anthony Bishop, CEO +604 659 1926 anthony.bishop@cercainsights.com News Source: NASDAQ OMX 31.05.2010 Ad hoc announcement, Financial News and Media Release distributed by DGAP. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------------- Language: English Company: Chakra Biotech Sdn Bhd United States Phone: Fax: E-mail: Internet: ISIN: US9901230931 WKN: End of News DGAP News-Service ---------------------------------------------------------------------------
Latest News
Latest Reports
No Reports found
Upcoming Events
No Events found
Webcasts
No Webcasts found